-
1
-
-
0033972577
-
Pretargeted Radioimmunotherapy (PRIT) using antibody-streptavidin conjugate and radiobiotin: Phase I study to optimize therapy protocol
-
In press
-
Breitz HB., Weiden PL, Beaumier P, Axworthy DB, Seiler C, Su F-M, Graves S, Bryan K, Reno J. Pretargeted Radioimmunotherapy (PRIT) using Antibody-Streptavidin Conjugate and Radiobiotin: Phase I Study to Optimize Therapy Protocol. J Nucl Med 41:In press,2000.
-
(2000)
J Nucl Med
, vol.41
-
-
Breitz, H.B.1
Weiden, P.L.2
Beaumier, P.3
Axworthy, D.B.4
Seiler, C.5
Su, F.-M.6
Graves, S.7
Bryan, K.8
Reno, J.9
-
2
-
-
0003323937
-
Pretargeted radioimmunotherapy with antibody-streptavidin and Y-90 DOTA-biotin (Avicidin): Result of a dose escalation study
-
Breitz H, Knox S, Weiden P, Goris M, Murtha A, Bryan J, Axworthy D, Seiler C, Su F-M, Beaumier P, Reno J. Pretargeted radioimmunotherapy with antibody-streptavidin and Y-90 DOTA-biotin (Avicidin): Result of a dose escalation study. J Nucl Med 1998;39:71P.
-
(1998)
J Nucl Med
, vol.39
-
-
Breitz, H.1
Knox, S.2
Weiden, P.3
Goris, M.4
Murtha, A.5
Bryan, J.6
Axworthy, D.7
Seiler, C.8
Su, F.-M.9
Beaumier, P.10
Reno, J.11
-
3
-
-
0025060324
-
The role of immunophenotypic markers in the classification of non-Hodgkin's lymphomas
-
Jaffe ES. The role of immunophenotypic markers in the classification of non-Hodgkin's lymphomas. Semin Oncol 1990;17:11-19.
-
(1990)
Semin Oncol
, vol.17
, pp. 11-19
-
-
Jaffe, E.S.1
-
5
-
-
0025288944
-
Avidin and Streptavidin
-
Wilchek M and Bayer E, eds. Methods of Enzymology
-
Green NM. Avidin and Streptavidin. In: Wilchek M and Bayer E, eds. Methods of Enzymology. Avidin-Biotin Technology. 1990;184:51-67.
-
(1990)
Avidin-biotin Technology
, vol.184
, pp. 51-67
-
-
Green, N.M.1
-
7
-
-
0003456152
-
90Y Dual isotope scintillation counting method for patient samples from pretargeted cancer therapy phase I trial
-
90Y Dual isotope scintillation counting method for patient samples from pretargeted cancer therapy phase I trial. J Nucl Med 1996;37:145P.
-
(1996)
J Nucl Med
, vol.37
-
-
Su, F.-M.1
Hickey, J.J.2
Taylor, C.3
Beaumier, P.4
-
9
-
-
0026634188
-
Clinical experience with Re-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials
-
Breitz HB, Weiden PL, Vanderheyden J-L, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB,Ratliff BA, Seiler CA, Foisie DC, et al. Clinical experience with Re-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med 1992;33:1099-1109.
-
(1992)
J Nucl Med
, vol.33
, pp. 1099-1109
-
-
Breitz, H.B.1
Weiden, P.L.2
Vanderheyden, J.-L.3
Appelbaum, J.W.4
Bjorn, M.J.5
Fer, M.F.6
Wolf, S.B.7
Ratliff, B.A.8
Seiler, C.A.9
Foisie, D.C.10
-
10
-
-
0020396015
-
Toxicity and response criteria of the Eastern Cooperative Group
-
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Group. Am J Clin Oncol 1982;5:649-655.
-
(1982)
Am J Clin Oncol
, vol.5
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Tormey, D.C.3
Horton, J.4
Davis, T.E.5
McFadden, E.T.6
Carbone, P.P.7
-
11
-
-
0042449063
-
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
-
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R,Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17(4):1245-1253.
-
(1999)
J Clin Oncol
, vol.17
, Issue.4
, pp. 1245-1253
-
-
Cheson, B.D.1
Horning, S.J.2
Coiffier, B.3
Shipp, M.A.4
Fisher, R.I.5
Connors, J.M.6
Lister, T.A.7
Vose, J.8
Grillo-Lopez, A.9
Hagenbeek, A.10
Cabanillas, F.11
Klippensten, D.12
Hiddemann, W.13
Castellino, R.14
Harris, N.L.15
Armitage, J.O.16
Carter, W.17
Hoppe, R.18
Canellos, G.P.19
-
12
-
-
0031872907
-
Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates
-
Press OW. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates. Cancer J Sci Am 4 Suppl 1998;2:S19-26.
-
(1998)
Cancer J Sci Am 4 Suppl
, vol.2
-
-
Press, O.W.1
-
13
-
-
0031759837
-
131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
-
131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3246-3256.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3246-3256
-
-
DeNardo, G.L.1
DeNardo, S.J.2
Goldstein, D.S.3
Kroger, L.A.4
Lamborn, K.R.5
Levy, N.B.6
McGahan, J.P.7
Salako, Q.8
Shen, S.9
Lewis, J.P.10
-
14
-
-
0032588605
-
67Cu-21T-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma
-
DeNardo SJ, DeNardo GL, Kukis DL, Shen S, Kroger LA, DeNardo DA, Goldstein DS, Mirick GR, Salako Q, Mausner LF, Srivastava SC, Meares CF. 67Cu-21T-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 1999;40:302-10.
-
(1999)
J Nucl Med
, vol.40
, pp. 302-310
-
-
DeNardo, S.J.1
DeNardo, G.L.2
Kukis, D.L.3
Shen, S.4
Kroger, L.A.5
DeNardo, D.A.6
Goldstein, D.S.7
Mirick, G.R.8
Salako, Q.9
Mausner, L.F.10
Srivastava, S.C.11
Meares, C.F.12
-
15
-
-
0027208577
-
Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody
-
Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-65.
-
(1993)
N Engl J Med
, vol.329
, pp. 459-465
-
-
Kaminski, M.S.1
Zasadny, K.R.2
Francis, I.R.3
Milik, A.W.4
Ross, C.W.5
Moon, S.D.6
Crawford, S.M.7
Burgess, J.M.8
Petry, N.A.9
Butchko, G.M.10
-
16
-
-
8944248819
-
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
-
Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-81.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1974-1981
-
-
Kaminski, M.S.1
Zasadny, K.R.2
Francis, I.R.3
Fenner, M.C.4
Ross, C.W.5
Milik, A.W.6
Estes, J.7
Tuck, M.8
Regan, D.9
Fisher, S.10
Glenn, S.D.11
Wahl, R.L.12
-
17
-
-
0000968039
-
Multicenter phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL)
-
Kaminski M, Zelenetz A, Press O, Selah M, Leonard J, Fehrenbacher L, Stagg R, Kross S, Tidmarsh G, Knox S, Vose J. Multicenter phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 1998;92 Suppl 1:316a. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
-
(1998)
Blood
, vol.92
, Issue.SUPPL. 1
-
-
Kaminski, M.1
Zelenetz, A.2
Press, O.3
Selah, M.4
Leonard, J.5
Fehrenbacher, L.6
Stagg, R.7
Kross, S.8
Tidmarsh, G.9
Knox, S.10
Vose, J.11
-
18
-
-
0027484445
-
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
-
Kaminski M, Zelenetz A, Press O, Selah M, Leonard J, Fehrenbacher L, Stagg R, Kross S, Tidmarsh G, Knox S, Vose J. Multicenter phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 1998;92 Suppl 1:316a. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
-
(1993)
N Engl J Med
, vol.329
, pp. 1219-1224
-
-
Press, O.W.1
Eary, J.F.2
Appelbaum, F.R.3
Martin, P.J.4
Badger, C.C.5
Nelp, W.B.6
Glenn, S.7
Butchko, G.8
Fisher, D.9
Porter, B.10
-
19
-
-
0029163551
-
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
-
Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995;346:336-40.
-
(1995)
Lancet
, vol.346
, pp. 336-340
-
-
Press, O.W.1
Eary, J.F.2
Appelbaum, F.R.3
Martin, P.J.4
Nelp, W.B.5
Glenn, S.6
Fisher, D.R.7
Porter, B.8
Matthews, D.C.9
Gooley, T.10
-
20
-
-
9044254117
-
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
-
Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-Lopez A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457-70.
-
(1996)
Clin Cancer Res
, vol.2
, pp. 457-470
-
-
Knox, S.J.1
Goris, M.L.2
Trisler, K.3
Negrin, R.4
Davis, T.5
Liles, T.M.6
Grillo-Lopez, A.7
Chinn, P.8
Varns, C.9
Ning, S.C.10
Fowler, S.11
Deb, N.12
Becker, M.13
Marquez, C.14
Levy, R.15
-
21
-
-
0002487802
-
90Yttrium radioimmunotherapy in non-Hodgkin's lymphoma (NHL)
-
90Yttrium radioimmunotherapy in non-Hodgkin's lymphoma (NHL). J Nucl Med 1999;40:64P.
-
(1999)
J Nucl Med
, vol.40
-
-
Wiseman, G.A.1
White, C.A.2
Witzig, T.A.3
Stabin, M.G.4
Spies, S.5
Silverman, D.H.6
Raubitschek, A.7
Gordon, L.8
Emmanouilides, C.9
Janakiraman, N.10
-
22
-
-
0031993168
-
Antibody pretargeted radiotherapy: A new approach and a second chance
-
Fritzberg AR. Antibody pretargeted radiotherapy: a new approach and a second chance. J Nucl Med 1998;39:20N-22N.
-
(1998)
J Nucl Med
, vol.39
-
-
Fritzberg, A.R.1
-
23
-
-
0033963824
-
Phase II trial of Yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer
-
in press
-
Knox SJ, Goris ML, Weiner LM, Tempero M, Weiden PL, Gentner L, Breitz H, Axworthy D, Seiler C, Bryan K, Fisher DR, Horak ID. Phase II trial of Yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res, in press.
-
Clin Cancer Res
-
-
Knox, S.J.1
Goris, M.L.2
Weiner, L.M.3
Tempero, M.4
Weiden, P.L.5
Gentner, L.6
Breitz, H.7
Axworthy, D.8
Seiler, C.9
Bryan, K.10
Fisher, D.R.11
Horak, I.D.12
-
24
-
-
0003323594
-
A phase II trial of pretargeted radioimmunotherapy (PRIT™) in patients with metastatic hormone resistant prostate Cancer (HRPC)
-
1999
-
Weiden PL, Small EJ, Hudes GR, Knox SJ, Hawkins R, Breitz H, Adams G, French J, Gaffigan S, Bryan K, Horak ID, Gentner L. A phase II trial of pretargeted radioimmunotherapy (PRIT™) in patients with metastatic hormone resistant prostate cancer (HRPC). J Clin Oncol 1999;18:313a(1999).
-
(1999)
J Clin Oncol
, vol.18
-
-
Weiden, P.L.1
Small, E.J.2
Hudes, G.R.3
Knox, S.J.4
Hawkins, R.5
Breitz, H.6
Adams, G.7
French, J.8
Gaffigan, S.9
Bryan, K.10
Horak, I.D.11
Gentner, L.12
-
25
-
-
0003323594
-
A phase II trial of pretargeted radioimmunotherapy (PRIT™) in patients with metastatic hormone resistant prostate Cancer (HRPC)
-
Weiden PL, Small EJ, Hudes GR, Knox SJ, Hawkins R, Breitz H, Adams G, French J, Gaffigan S, Bryan K, Horak ID, Gentner L. A phase II trial of pretargeted radioimmunotherapy (PRIT™) in patients with metastatic hormone resistant prostate cancer (HRPC). J Clin Oncol 1999;18:313a.
-
(1999)
J Clin Oncol
, vol.18
-
-
Weiden, P.L.1
Small, E.J.2
Hudes, G.R.3
Knox, S.J.4
Hawkins, R.5
Breitz, H.6
Adams, G.7
French, J.8
Gaffigan, S.9
Bryan, K.10
Horak, I.D.11
Gentner, L.12
|